Amgen Territory. Unless expressly set forth in this Agreement or the Existing License Agreement otherwise, Amgen shall have the sole decision-making authority with regard to Development, regulatory, Medical Affairs Activities, Manufacturing and Commercialization of the Product in the Amgen Territory. Unless expressly permitted in this Agreement or the Existing License Agreement, Novartis and its Affiliates shall not Develop or Commercialize or conduct Medical Affairs Activities with respect to the Product in any country in the Amgen Territory.
Amgen Territory. Except to the extent expressly provided otherwise in the Existing License Agreement, in the Amgen Territory, Amgen shall control and be solely responsible for all Patent and Trademark Matters with respect to (i) its patent rights, trademark rights and other intellectual property and (ii)
Amgen Territory. Except to the extent expressly provided otherwise in the Existing License Agreement, Amgen shall have the sole right, but not the obligation, to enforce its patent rights, trademark rights and other intellectual properties, and the Joint Patents in the Amgen Territory against any actual, alleged or threatened infringement or misappropriation by Third Parties in the Amgen Territory, and to settle any such matters in its sole discretion subject to Section 9.3 (Defense and Settlement of Third Party Claims). Except to the extent expressly provided otherwise in the Existing License Agreement, Novartis shall have no right to enforce such rights in the Amgen Territory.
Amgen Territory. Licensee shall promptly notify Amgen in writing if it reasonably believes that any patent, trademark, know-how or other intellectual property Controlled by Amgen that relates to the Licensed Product are infringed or misappropriated by a Third Party in the Amgen Territory. [*].
Amgen Territory. Except as set forth in (a) above, Amgen will --------------- file and prosecute the patent applications and applications for trademarks and copyright registration, and maintain resultant patents, trademarks and copyrights, included within the TPO/MGDF Technology in the Amgen Territory. The associated costs and expenses will be borne by (i) Amgen with respect to TPO/MGDF Technology in the Amgen Core Territory and (ii) Kirin-Amgen with respect to TPO/MGDF Technology in the Amgen Additional Territory.
Amgen Territory. Amgen will enforce the technology included --------------- within the TPO/MGDF Technology in the Amgen Territory. Amgen shall bear all costs and expenses associated therewith.
Amgen Territory. Amgen will defend any suitor action claiming --------------- infringement of any third party patent right through the making, having made, using, selling or having sold TPO/MGDF Products in the Amgen Territory. Amgen shall bear all costs and expenses associated therewith.
Amgen Territory. Except to the extent expressly provided otherwise in the Global Agreement, Amgen shall have the sole right, but not the obligation, to enforce its patent rights, trademark rights and other intellectual properties, and the Joint Patents in the Amgen Territory against any actual, alleged or threatened infringement or misappropriation by Third Parties in the Amgen Territory, and to settle any such matters in its sole discretion subject to Section 9.3 (Defense and Settlement of Third Party Claims). Except to the extent expressly provided otherwise in the Global Agreement, Novartis shall have no right to enforce such rights in the Amgen Territory.
Amgen Territory. Except to the extent expressly provided otherwise in the Existing License Agreement, Amgen shall have the sole right, but not the obligation, to enforce its patent rights, trademark rights and other intellectual properties, and the Joint Patents in the Amgen Territory against any actual, alleged or threatened infringement or misappropriation by Third Parties in the Amgen Territory, and to settle any such matters in its sole discretion subject to Section 9.3 (
Amgen Territory. Amgen will have the first right, but not the --------------- obligation, to enforce the technology included within NM321 Technology within the Amgen Territory, and payment of the associated costs and expenses will be borne as agreed between Amgen and Kirin-Amgen on a case by case basis.
